1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial

M Parry,E Grist,S Lall,F Feng,Christopher J Sweeney ,Alex Hoyle ,R Jones,Ashwin Sachdeva ,Christopher D Brawley ,M.r Sydes ,G Attard,James Proudfoot ,L Mendes,Max Parmar ,Nigel Clarke ,Y Liu,Nicholas D James ,Claire Amos ,Elai Davicioni ,Lc Brown

doi:10.1016/j.annonc.2022.07.1491

1358O Clinical qualification of transcriptome signatures for advanced prostate cancer (APC) starting androgen deprivation therapy (ADT) with or without abiraterone acetate and prednisolone (AAP): An ancillary study of the STAMPEDE AAP trial

M Parry, E Grist + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2022.07.1491

Copy DOI

Journal: Annals of Oncology	Publication Date: Sep 1, 2022
Citations: 1	License type: publisher-specific-oa

Affiliation: CRUK Lung Cancer Centre of Excellence, University College London, MBC BioLabs (United States), Dana-Farber Cancer Institute, The Christie NHS Foundation Trust, University of Glasgow, Medical Research Council, MRC Clinical Trials Unit, Veracyte (United States), Cancer Research UK Manchester Institute, University of Manchester, Institute of Cancer Research, Cancer Research UK, London Cancer

#Starting Androgen Deprivation Therapy #Androgen Deprivation Therapy + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

Addition of AAP to ADT is standard of care for APC (metastatic, M1 and high-risk non-metastatic, M0). We tested transcriptome signatures as prognostic and predictive biomarkers for patients (pt) starting ADT +/- AAP.

Full Text

Paper version not known

Open DOI Link

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Annals of Oncology

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.